山东大学耳鼻喉眼学报 ›› 2021, Vol. 35 ›› Issue (1): 119-124.doi: 10.6040/j.issn.1673-3770.0.2020.089

• • 上一篇    下一篇

下咽癌中差异表达的蛋白激酶及抑制剂的研究进展

王亚越1,2综述孙娟2审校   

  1. 1. 内蒙古医科大学研究生院, 内蒙古 呼和浩特 010050;
    2. 内蒙古医科大学附属医院 耳鼻咽喉科, 内蒙古 呼和浩特 010050
  • 发布日期:2021-02-01
  • 通讯作者: 孙娟. E-mail:sunjuan28@sina.com
  • 基金资助:
    内蒙古自然科学基金(2017MS0838,2019LH08027)

Research progress on differentially-expressed protein kinases and inhibitors in hypopharyngeal carcinoma

WANG Yayue1,2Overview,SUN Juan2Guidance   

  1. 1. Graduate School of Inner Mongolia Medical University, Hohhot 010050, Inner Mongolia, China;
    2. Department of Otolaryngology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, Inner Mongolia, China
  • Published:2021-02-01

PDF (PC)

336

摘要： 在头颈恶性肿瘤中,下咽癌恶性程度高,患者生存质量较差且通常预后不良。下咽癌的治疗采用手术为主的方式,并辅助以放化疗。术后患者喉功能受损严重,寻找能够尽量保护喉功能的治疗方法是目前研究的重点。靶向治疗对下咽癌患者保护喉功能、提高生存质量意义重大。研究发现,下咽癌发生过程中涉及多种蛋白激酶介导的信号通路及基因,对可能在这一过程中有重要意义的蛋白激酶PKC-β、CDK4/6、Cdc42、Rac1、STK33、CK2和PHLPP作一综述,以期为蛋白激酶抑制剂作为下咽癌治疗的靶点提供新的方向。

关键词: 下咽癌, 肿瘤, 蛋白激酶, 蛋白激酶抑制剂, 靶点

Abstract: Among tumors of the head and neck, hypopharyngeal cancer is highly malignant and patients suffering from it have a poor quality of life, usually with a poor prognosis. Surgery is the main method of treatment of hypopharyngeal cancer, assisted by radiotherapy and chemotherapy. After surgery, the patient's laryngeal function is seriously impaired. Finding a treatment method that can protect the laryngeal function as much as possible is the focus of current research. Targeted therapy is of great significance to protecting the laryngeal function and improving the quality of life of patients with hypopharyngeal carcinoma. The study found that a variety of protein-kinase-mediated signaling pathways and genes are involved in the development of this pathology. Now, protein kinases PKC-β, CDK4/6, Cdc42, Rac1, and STK33, which might have an important role in this process, CK2 and PHLPP are reviewed. There is hope that protein kinase inhibitors would provide new directions for the treatment of hypopharyngeal cancer.

Key words: Hypopharyngeal carcinoma, Tumor, Protein kinase, Protein kinase inhibitor, Target

中图分类号: 

  • R739
[1] 吴静, 刘业海. 头颈部鳞状细胞癌的靶向治疗研究进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 97-102. doi:10.6040/j.issn.1673-3770.0.2018.058. WU Jing, LIU Yehai. Targeted therapy for head and neck squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(5): 97-102. doi:10.6040/j.issn.1673-3770.0.2018.058.
[2] Vengaloor Thomas T, Nittala MR, Bhanat E, et al. Management of advanced-stage hypopharyngeal carcinoma: 25-year experience from a tertiary care medical center[J]. Cureus, 2020, 12(1): e6679. doi:10.7759/cureus.6679.
[3] 周梁. 下咽癌的治疗进展[J]. 中国耳鼻咽喉颅底外科杂志, 2019, 25(4): 333-338. doi:10.11798/j.issn.1007-1520.201904001. ZHOU Liang. Progress on treatment of hypopharyngeal carcinoma[J]. Chinese Journal of Otorhinolaryngology-Skull Base Surgery, 2019, 25(4): 333-338. doi:10.11798/j.issn.1007-1520.201904001.
[4] 崔晓波. 诱导化疗在局部晚期下咽癌治疗中的意义[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 10-17. doi:10.6040/j.issn.1673-3770.1.2019.027. CUI Xiaobo. Significance of induction chemotherapy in late treatment of locally advanced hypo-pharyngeal cancer[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 10-17. doi:10.6040/j.issn.1673-3770.1.2019.027.
[5] Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions[J]. Mol Cancer, 2018, 17: 48. doi:10.1186/s12943-018-0804-2.
[6] Ardito F, Giuliani M, Perrone D, et al. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy(Review)[J]. Int J Mol Med, 2017, 40(2): 271-280. doi:10.3892/ijmm.2017.3036.
[7] Cheng HJ, Wang WW, Wang GK, et al. Silencing ras-related C3 botulinum toxin substrate 1 inhibits growth and migration of hypopharyngeal squamous cell carcinoma via the P38 mitogen-activated protein kinase signaling pathway[J]. Med Sci Monit, 2018, 24: 768-781. doi:10.12659/msm.907468.
[8] Huang LY, Chen C, Zhang GD, et al. STK33 overexpression in hypopharyngeal squamous cell carcinoma: possible role in tumorigenesis[J]. BMC Cancer, 2015, 15: 13. doi:10.1186/s12885-015-1009-3.
[9] Lian HW, Su M, Zhu YJ, et al. Protein kinase CK2, a potential therapeutic target in carcinoma management[J]. Asian Pac J Cancer Prev, 2019, 20(1): 23-32. doi:10.31557/apjcp.2019.20.1.23.
[10] Newton AC. Protein kinase C: perfectly balanced[J]. Crit Rev Biochem Mol Biol, 2018, 53(2): 208-230. doi:10.1080/10409238.2018.1442408.
[11] 黄来全, 刘大翔. BTK与PKCβ在多发性骨髓瘤中表达及调控的信号通路机制研究[J]. 东南大学学报(医学版), 2018, 37(4): 578-583. doi:10.3969/j.issn.1671-6264.2018.04.005. HUANG Laiquan, LIU Daxiang. Expression of BTK and PKCβin multiple myeloma and the mechanism of its regulated signaling pathway[J]. Journal of Southeast University(Medical Science Edition), 2018, 37(4): 578-583. doi:10.3969/j.issn.1671-6264.2018.04.005.
[12] Zhu J, He YZ, Li J, et al. Combination of enzastaurin and ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma[J]. Blood, 2018, 132(Supplement 1): 1666. doi:10.1182/blood-2018-99-110571.
[13] 李冠军, 董桂青, 李宇玥, 等. 抗肿瘤新药Enzastaurin的药理学及其临床研究进展[J]. 中国药房, 2011, 22(38): 3613-3616.
[14] Tarrado-Castellarnau M, de Atauri P, Tarragó-Celada J, et al. De novo MYC addiction as an adaptive response of cancer cells to CDK 4/6 inhibition[J]. Mol Syst Biol, 2017, 13(10): 940. doi:10.15252/msb.20167321.
[15] Goel S, DeCristo MJ, McAllister SS, et al. CDK4/6 inhibition in cancer: beyond cell cycle arrest[J]. Trends Cell Biol, 2018, 28(11): 911-925. doi:10.1016/j.tcb.2018.07.002.
[16] 付彬, 莫春梅, 覃艳春, 等. CDK4/6抑制剂治疗恶性肿瘤研究进展[J]. 海南医学院学报, 2019, 25(21): 1676-1680. doi:10.13210/j.cnki.jhmu.20191030.001. FU Bin, MO Chunmei, QIN Yanchun, et al. Progress of CDK4/6 inhibitors in treatment of malignant tumors[J]. Journal of Hainan Medical University, 2019, 25(21): 1676-1680. doi:10.13210/j.cnki.jhmu.20191030.001.
[17] Klein ME, Kovatcheva M, Davis LE, et al. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought[J]. Cancer Cell, 2018, 34(1): 9-20. doi:10.1016/j.ccell.2018.03.023.
[18] Peurois F, Veyron S, Ferrandez Y, et al. Characterization of the activation of small GTPases by their GEFs on membranes using artificial membrane tethering[J]. Biochem J, 2017, 474(7): 1259-1272. doi:10.1042/bcj20170015.
[19] Møller LLV, Klip A, Sylow L. Rho GTPases-emerging regulators of glucose homeostasis and metabolic health[J]. Cells, 2019, 8(5): 434. doi:10.3390/cells8050434.
[20] Maldonado MDM, Dharmawardhane S. Targeting rac and Cdc42 GTPases in cancer[J]. Cancer Res, 2018. doi:10.1158/0008-5472.can-18-0619.
[21] 李楠静, 刘明, 张又, 等. Rho GTP酶与肿瘤细胞耐药性的关系研究进展[J]. 山东医药, 2018, 57(7): 99-101. doi:10.3969/j.issn.1002-266X.2018.07.031.
[22] 郑艳秋, 胡文良, 崔晓波, 等. CDC42抑制剂ML141对喉癌Hep-2细胞增殖的抑制作用[J]. 现代生物医学进展, 2016, 16(4): 644-646, 651. doi:10.13241/j.cnki.pmb.2016.04.010. ZHENG Yanqiu, HU Wenliang, CUI Xiaobo, et al. CDC42 inhibitor ML141 suppresses laryngeal cancer hep-2 cell proliferation[J]. Progress in Modern Biomedicine, 2016, 16(4): 644-646, 651. doi:10.13241/j.cnki.pmb.2016.04.010.
[23] Chen C, Huang LY, Zhang GD, et al. STK33 potentiates the malignancy of hypopharyngeal squamous carcinoma: Possible relation to calcium[J]. Cancer Biol Ther, 2016, 17(9): 976-984. doi:10.1080/15384047.2016.1210739.
[24] Chua M, Ortega C, Sheikh A, et al. CK2 in cancer: cellular and biochemical mechanisms and potential therapeutic target[J]. Pharmaceuticals, 2017, 10(4): 18. doi:10.3390/ph10010018.
[25] Zhang F, Yang B, Shi SL, et al. RNA interference(RNAi)mediated stable knockdown of protein casein kinase 2-alpha(CK2α)inhibits migration and invasion and enhances cisplatin-induced apoptosis in HEp-2 laryngeal carcinoma cells[J]. Acta Histochem, 2014, 116(6): 1000-1006. doi:10.1016/j.acthis.2014.04.001.
[26] Ortega CE, Seidner Y, Dominguez I. Mining CK2 in cancer[J]. PLoS One, 2014, 9(12): e115609. doi:10.1371/journal.pone.0115609.
[27] Grzechnik AT, Newton AC. PHLPPing through history: a decade in the life of PHLPP phosphatases[J]. Biochem Soc Trans, 2016, 44(6): 1675-1682. doi:10.1042/bst20160170.
[28] Qiu YH, Li XY, Yi B, et al. Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer[J]. Oncotarget, 2015, 6(22): 19148-19162. doi:10.18632/oncotarget.3721.
[29] Zhou JY, Yu XM, Wang J, et al. Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma[J]. PLoS One, 2015, 10(3): e0119405. doi:10.1371/journal.pone.0119405.
[30] Gao TY, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth[J]. Mol Cell, 2005, 18(1): 13-24. doi:10.1016/j.molcel.2005.03.008.
[31] Qiao M, Wang YQ, Xu XE, et al. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis[J]. Mol Cell, 2010, 38(4): 512-523. doi:10.1016/j.molcel.2010.03.017.
[32] 胡文良, 郑艳秋, 崔晓波, 等. 下咽癌中差异表达的蛋白激酶及其抑制剂的生物信息学筛选[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 24-28, 36. doi: 10.6040/j.issn.1673-3770.0.2015.340. HU Wenliang, ZHENG Yanqiu, CUI Xiaobo, et al. Bioinformatic screening of differentially expressed protein kinases and their inhibitors in hypopharyngeal cancer[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2016, 30(3): 24-28, 36. doi: 10.6040/j.issn.1673-3770.0.2015.340.
[33] Marei H, Malliri A. Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms[J]. Small Gtpases, 2017, 8(3): 139-163. doi:10.1080/21541248.2016.1211398.
[34] Michaelis M, Rothweiler F, Löschmann N, et al. Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status[J]. Oncotarget, 2015, 6(19): 17605-17620. doi:10.18632/oncotarget.2889.
[35] Spring LM, Zangardi ML, Moy B, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations[J]. Oncol, 2017, 22(9): 1039-1048. doi:10.1634/theoncologist.2017-0142.
[36] Ku BM, Yi SY, Koh J, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma[J]. Oncotarget, 2016, 7(12): 14803-14813. doi:10.18632/oncotarget.7543.
[37] 徐永茹, 徐平, 徐锋, 等. CDC42与癌症[J]. 军事医学, 2016, 40(3): 256-260. doi:10.7644/j.issn.1674-9960.2016.03.023. XU Yongru, XU Ping, XU Feng, et al. The role of CDC42 in cancer[J]. Military Medical Sciences, 2016, 40(3): 256-260. doi:10.7644/j.issn.1674-9960.2016.03.023.
[38] Schnitzler A, Gratz A, Bollacke A, et al. A π-halogen bond of dibenzofuranones with the gatekeeper Phe113 in human protein kinase CK2 leads to potent tight binding inhibitors[J]. Pharmaceuticals, 2018, 11(1): 23. doi:10.3390/ph11010023.
[1] 许亚琳,陈庆泳,王冬青,林立强,陈志鹏,吕怀庆. 耳后沟切口联合腮腺下极瓣修复在腮腺浅叶良性肿瘤手术中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 1-6.
[2] 彭中华,陈竹,袁洛花,余绍兰,马玉玲. 原发性鼻腔高级别非肠型腺癌1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 95-98.
[3] 孙凡敏,张娟美,高杰,赵军. 近视中Shh、PI3K/AKT、MMP-2通路及关联性研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 142-148.
[4] 胡祎,孔旭辉. 补体在喉鳞状细胞癌发生发展中作用机制的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 148-155.
[5] 王华,张丰珍,龙婷,赵靖,李宏彬,王生才,王桂香. 后颅窝肿瘤术后儿童气管切开原因及预后转归分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 168-173.
[6] 柯冰冰,陈铭,王洪阳,李春燕,殷善开. CAMK4介导胆红素所致听觉中枢神经元氧化应激损伤[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 1-10.
[7] 于浩南,钟莹莹,王新萌,张敏,姜清敏,李娜,李艳. TNF-α诱导的人脐带间充质干细胞培养基对小鼠角膜缘干细胞缺乏的治疗作用[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 141-147.
[8] 杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161.
[9] 谢枫,许贞菊,吴策,刘杰,臧传善,张龙宵,韩敏. 喉神经内分泌肿瘤26例临床病理特征及生存分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 79-86.
[10] 黄佳丽,刘梓琪,徐娟,陈曦,张立庆,周涵. 咽部梭形细胞鳞状细胞癌的临床及预后分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 94-100.
[11] 彭宇婷,李坚昊,王燕. 鼻-眼眶-颅底恶性肿瘤继发眶尖综合征1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 105-111.
[12] 杨煜雲,黄艳利,李军政. 铜配合物在抗肿瘤治疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 145-152.
[13] 汪洋,胡越,李晓明,齐雯雯,张杰,张皓,王倩倩,许风雷,贾涛,夏明. 3D打印钛金属假体修复大面积气管缺损1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 121-125.
[14] 张静祎,董湘依,牟亚魁,宋西成. 细胞焦亡在耳鼻咽喉科疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 140-148.
[15] 杨开炎, 唐凤珠, 覃启才, 李旭祥, 冯大益, 农丰靖, 杨秋云. 异常纺锤体样小头畸形相关蛋白在鼻咽癌中的表达及其临床意义[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 18-25.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发